Agenda

Date and TimeTitle
Aug 4, 2021 (Eastern)
4:30pm - 5:30pm
Personalizing and optimizing treatment for metastatic NSCLC patients with EGFR mutations - is there more we can do?

Learning Objectives: 

  • Review the EGFRmut+ mNSCLC landscape and treatment outcomes of different mutations including common, rare and co-occurring mutations
  • Understand the scientific rationale behind combining therapies and impact on treatment outcomes for EGFRmut+ mNSCLC patients
  • Discuss high-risk clinical and disease characteristics of patients with EGFRmut+ mNSCLC including their negative impact on prognosis and response to therapy and their implications for optimizing treatment decision making and clinical outcomes

This is a Non-CME/CE presentation. Available for on-demand viewing August 10th - October 10th.

Sponsored by Lilly

Aug 4, 2021 (Eastern)
6:00pm - 7:41pm
Session I: Targeted Therapy in NSCLC

6:00 pm ET | Introduction
Christine Lovly, MD, PhD

6:05 pm ET | Practical Considerations for Genotyping
Theresa A. Boyle, MD, PhD, FCAP

6:20 pm ET | How Do You Care for Patients with Each Alteration? EGFR/HER2 – ErbB Family Members in NSCLC Management
Helena Yu, MD

6:35 pm ET | How Do You Care for Patients with Each Alteration? ALK/ROS/RET/NTRK – Fusion Kinases in Lung Cancer
Lyudmila Bazhenova, MD

6:55 pm ET | How Do You Care for Patients with Each Alteration? KRAS, BRAF and MET
Mark M. Awad, MD, PhD

7:10 pm ET | Oncology Pharmacist Perspective: Drug-Drug Interactions, Compliance, and More
Amanda Cass, PharmD, BCPS, BCOP

7:26 pm ET | Q&A/Panel Discussion
Mark M. Awad, MD, PhD
Lyudmila Bazhenova, MD
Theresa A. Boyle, MD, PhD, FCAP
Amanda Cass, PharmD, BCPS, BCOP
Christine Lovly, MD, PhD
Helen Yu, MD

Supported by an independent educational grant from Amgen
Supported by an independent educational grant from AstraZeneca Pharmaceuticals LP
Supported by an independent educational grant from Exact Sciences Corporation
Supported by an independent educational grant from Novartis Oncology

ACCREDITATION INFORMATION

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians
Medscape, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 2.0 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.25 contact hours in the area of pharmacology.

For Pharmacists
Medscape designates this continuing education activity for Knowledge-based 2.0 contact hours and 0.2 CEUs. See individual session Universal Activity number JA0007105-0000-21-440-L01-P.

Aug 4, 2021 (Eastern)
7:55pm - 9:30pm
Session II: Immunotherapy in NSCLC

7:55 pm ET | Introduction
Charu Aggarwal, MD, MPH

8:02 pm ET | Monotherapy
Hossein Borghaei, DO, MS

8:17 pm ET | IO Combinations with Chemotherapy
Melina Marmarelis, MD

8:30 pm ET | IO-IO Combinations
Suresh Ramalingam, MD

8:44 pm ET | Biomarkers
Balazs Halmos, MD, MS

9:00 pm ET | Nurse/NP Perspective: Management of Toxicities
Beth Sandy, MSN, CRNP

9:15 pm ET | Q&A/Panel Discussion
Charu Aggarwal, MD, MPH
Hossein Borghaei, DO, MS
Balazs Halmos, MD, MS
Melina Marmarelis, MD
Suresh Ramalingam, MD
Beth Sandy, MSN, CRNP

9:35 pm ET | Day 1 Closing Remarks
Lecia V. Sequist, MD, MPH

Supported by an independent educational grant from Amgen
Supported by an independent educational grant from AstraZeneca Pharmaceuticals LP
Supported by an independent educational grant from Exact Sciences Corporation
Supported by an independent educational grant from Novartis Oncology
Supported by an independent educational grant from Regeneron Pharmaceuticals and Sanofi Genzyme

ACCREDITATION INFORMATION

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians
Medscape, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 1.5 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.0 contact hours in the area of pharmacology.

Aug 5, 2021 (Eastern)
6:00pm - 7:40pm
Session III: Early-Stage and Locally Advanced NSCLC Management

6:00 pm ET | Introduction
Nathan Pennell, MD, PhD

6:05 pm ET | Expert Interview: Early-Stage NSCLC Management
Nathan Pennell, MD, PhD
Lecia V. Sequist, MD, MPH

6:15 pm ET | Adjuvant Targeted Treatment for Patients with Early-Stage  EGFR

Nathan Pennell, MD, PhD

6:32 pm ET | Immunotherapy: Updates in Early-Stage and Locoregionally Advanced NSCLC
Jamie Chaft, MD

6:50 pm ET | Advances in Surgical Care for Early-Stage Lung Cancer
Jessica Donington, MD, MSCR

7:08 pm ET | Integration of Systemic Therapy with SBRT for Early-Stage NSCLC
Clifford Robinson, MD

7:25 pm ET | Q&A/Panel Discussion
Jamie Chaft, MD
Jessica Donington, MD, MSCR
Nathan Pennell, MD, PhD
Clifford Robinson, MD
Lecia V. Sequist, MD, MPH

Supported by an independent educational grant from Amgen
Supported by an independent educational grant from AstraZeneca Pharmaceuticals LP
Supported by an independent educational grant from Exact Sciences Corporation
Supported by an independent educational grant from Novartis Oncology

ACCREDITATION INFORMATION

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians
Medscape, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 1.5 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.75 contact hours in the area of pharmacology.

Aug 5, 2021 (Eastern)
8:00pm - 9:00pm
Session IV: Management of SCLC

8:00 pm ET | Introduction
Stephen Liu, MD

8:05 pm ET | Clinical Case Approach for First-Line Management of SCLC
Ticiana Leal, MD

8:20 pm ET | Clinical Case Approach for Second-Line Management of SCLC
Taofeek Owonikoko, MD, PhD

8:35 pm ET | The Evolving Role of Radiation Oncology in SCLC
Kristen Higgins, MD

8:45 pm ET | Q&A/Panel Discussion
Kristen Higgins, MD
Ticiana Leal, MD
Stephen Liu, MD
Taofeek Owonikoko, MD, PhD

Supported by an independent educational grant from Amgen
Supported by an independent educational grant from AstraZeneca Pharmaceuticals LP
Supported by an independent educational grant from Exact Sciences Corporation
Supported by an independent educational grant from Novartis Oncology

ACCREDITATION INFORMATION

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians
Medscape, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.75 contact hours in the area of pharmacology.

Aug 5, 2021 (Eastern)
9:00pm - 9:46pm
Session V: Mesothelioma

9:00 pm ET | Introduction
Ibiayi Dagogo-Jack, MD

9:05 pm ET | Checkpoint Inhibitors in Pleural Mesothelioma
Patrick Forde, MBBCh

9:20 pm ET | Targeted Therapy and CAR T Cells in Mesothelioma
Marjorie G. Zauderer, MD, MS, FACP

9:35 pm ET | Q&A/Panel Discussion
Ibiayi Dagogo-Jack, MD
Patrick Forde, MBBCh
Marjorie G. Zauderer, MD, MS, FACP

9:50 pm ET | Day 2 Closing Remarks
Lecia V. Sequist, MD, MPH

Supported by an independent educational grant from Amgen
Supported by an independent educational grant from AstraZeneca Pharmaceuticals LP
Supported by an independent educational grant from Exact Sciences Corporation
Supported by an independent educational grant from Novartis Oncology

ACCREDITATION INFORMATION

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians
Medscape, LLC designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 0.75 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.5 contact hours in the area of pharmacology.

Aug 6, 2021 (Eastern)
1:30pm - 2:30pm
What Can We Learn from NSCLC? Using Comprehensive Genomic Profiling to Enhance Patient Care

Attend this symposium to learn about:

  • The growing need for NGS testing and genomic profiling in light of recent guidelines and new targeted treatment options
  • How the new Oncotype MAP™ Pan-Cancer Tissue test can be used to aid therapy selection for patients with advanced, metastatic, refractory, relapsed or recurrent cancer
  • Real-world NSCLC case studies demonstrating how genomic profiling has been used to enhance patient care

This is a Non-CME/CE presentation. Available for on-demand viewing August 10th - October 10th.

Sponsored by Exact Sciences

Aug 6, 2021 (Eastern)
3:00pm - 4:10pm
Session VI: Lung Cancer Screening and Early Detection

3:00 pm ET | Introduction
Brendon Stiles, MD

3:05 pm ET | Clinical Trial Updates on Lung Cancer Screening
Drew Moghanaki, MD, MPH

3:15 pm ET | Ongoing Challenges of Lung Cancer Screening
Andrea McKee, MD

3:25 pm ET | The Future of Lung Cancer Screening
Jacob Sands, MD

3:35 pm ET | Q&A/Panel Discussion
Andrea McKee, MD
Drew Moghanaki, MD, MPH
Jacob Sands, MD
Brendon Stiles, MD

Supported by an independent educational grant from Amgen
Supported by an independent educational grant from AstraZeneca Pharmaceuticals LP
Supported by an independent educational grant from Exact Sciences Corporation
Supported by an independent educational grant from Novartis Oncology
Supported by an independent educational grant from Regeneron Pharmaceuticals and Sanofi Genzyme

ACCREDITATION INFORMATION

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians
Medscape, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs; 0 contact hours in the area of pharmacology.

Aug 6, 2021 (Eastern)
4:15pm - 5:25pm
Session VII: The New Normal: The Past, Present and Future of Lung Cancer Care

4:15 pm ET | Introduction
Jared Weiss, MD

4:20 pm ET | Virtual Medicine: How to Optimize Care and the Patient Experience
Howard L. (Jack) West, MD

4:35 pm ET | COVID-19 Itself: Information and Advice
Justin Gainor, MD

4:50 pm ET | Equity in the Current Era: Assessing the Impact of COVID-19
Narjust Duma, MD

5:05 pm ET | Q&A/Panel Discussion
Narjust Duma, MD
Nathan Pennell, MD, PhD
Justin Gainor, MD
Howard L. (Jack) West, MD

5:30 pm ET | Conference Adjourns/Closing Remarks
Lecia V. Sequist, MD, MPH

Supported by an independent educational grant from Amgen
Supported by an independent educational grant from AstraZeneca Pharmaceuticals LP
Supported by an independent educational grant from Exact Sciences Corporation
Supported by an independent educational grant from Novartis Oncology
Supported by an independent educational grant from Regeneron Pharmaceuticals and Sanofi Genzyme

ACCREDITATION INFORMATION

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians
Medscape, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs; 0 contact hours in the area of pharmacology.